Amyloid β-peptide (25-35) (human)

Pricing Availability   Qty
Cat.No. 1429 - Amyloid beta-peptide (25-35) (human) | Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met | CAS No. 131602-53-4
Description: Human amyloid β-protein fragment functionally required for neurotoxicity
Purity: ≥95% (HPLC)
Citations (1)
Literature (2)

Biological Activity for Amyloid β-peptide (25-35) (human)

Amyloid β-peptide (25-35) (human) is a fragment of human amyloid β-peptide, functionally required for the neurotrophic and neurotoxic effects associated with Alzheimer's disease.

Technical Data for Amyloid β-peptide (25-35) (human)

M. Wt 1060.27
Formula C45H81N13O14S
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 131602-53-4
PubChem ID 10843733
Smiles [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Amyloid β-peptide (25-35) (human)

Solubility Soluble to 0.50 mg/ml in water

Product Datasheets for Amyloid β-peptide (25-35) (human)

Certificate of Analysis / Product Datasheet
Select another batch:

References for Amyloid β-peptide (25-35) (human)

References are publications that support the biological activity of the product.

Rush et al (1992) Intracerebral β-amyloid(25-35) produces tissue damage: is it neurotoxic? Neurobiol.Aging 13 591 PMID: 1281289

Schenk et al (1995) Therapeutic approaches related to amyloid-β peptide and Alzheimer's Disease J.Med.Chem. 38 4141 PMID: 7473539

Yankner et al (1990) Neurotrophic and neurotoxic effects of amyoid β protein: reversal by tachykinin neuropeptides. Science 250 279 PMID: 2218531

If you know of a relevant reference for Amyloid β-peptide (25-35) (human), please let us know.

View Related Products by Target

Keywords: Amyloid beta-peptide (25-35) (human), Amyloid beta-peptide (25-35) (human) supplier, Human, amyloid, β-protein, beta-protein, fragment, functionally, neurotoxicity, β-Amyloid, beta-Amyloid, b-amyloid, Precursor, Protein, APP, Secretase, Peptides, Amyloid, β-peptide, beta-peptide, (25-35), (human), amyloidbeta, amyloidb, Beta, 1429, Tocris Bioscience

1 Citation for Amyloid β-peptide (25-35) (human)

Citations are publications that use Tocris products. Selected citations for Amyloid β-peptide (25-35) (human) include:

Ostrovskaya et al (2014) Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J.Biomed.Sci. 21 74 PMID: 25096780

Do you know of a great paper that uses Amyloid β-peptide (25-35) (human) from Tocris? Please let us know.

Reviews for Amyloid β-peptide (25-35) (human)

There are currently no reviews for this product. Be the first to review Amyloid β-peptide (25-35) (human) and earn rewards!

Have you used Amyloid β-peptide (25-35) (human)?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Neurodegeneration Product Guide

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.